Key stats
Market capitalization
10.044MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.6887USD
About Adial Pharmaceuticals, Inc
ISIN
US00688A1144
Sector
Health Technology
Industry
Pharmaceuticals: Major
Website
adialpharma.com
CEO
Cary J. Claiborne
Headquarters
Charlottesville
Employees
18
Founded
2010
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0